TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
Tumor necrosis factor superfamily member 14 (LIGHT) has been in pre-clinical development for over a decade and shows promise as a modality of enhancing treatment approaches in the field of cancer immunotherapy. To date, LIGHT has been used to combat cancer in multiple tumor models where it can be co...
Main Authors: | Joseph G. Skeate, Mikk E. Otsmaa, Ruben Prins, Daniel J. Fernandez, Diane M. Da Silva, W. Martin Kast |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00922/full |
Similar Items
-
TNFSF14 and CD44 are overexpressed in glioblastoma and associated with immunosuppressive microenvironment
by: Alja Zottel, et al.
Published: (2025-02-01) -
Molecular and Clinical Characterization of LIGHT/TNFSF14 Expression at Transcriptional Level via 998 Samples With Brain Glioma
by: Ying Yang, et al.
Published: (2021-08-01) -
Genetic Variants in TNFSF4 and TNFSF8 Are Associated With the Risk of HCV Infection Among Chinese High-Risk Population
by: Zuqiang Fu, et al.
Published: (2021-03-01) -
Dissecting Abdominal Aortic Aneurysm Is Aggravated by Genetic Inactivation of LIGHT (TNFSF14)
by: Andrea Herrero-Cervera, et al.
Published: (2021-10-01) -
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)
by: Nadine Aschmoneit, et al.
Published: (2022-12-01)